Prospectively Surveying Health-Related Quality of Life and Symptom Relief in a Lot-Based Sample of Medical Cannabis-Using Patients in Urban Washington State Reveals Managed Chronic Illness and Debility

被引:18
作者
Aggarwal, S. K. [1 ]
Carter, G. T. [2 ]
Sullivan, M. D. [3 ,4 ]
Zumbrunnen, C. [5 ]
Morrill, R. [5 ]
Mayer, J. D. [5 ,6 ,7 ,8 ,9 ,10 ]
机构
[1] NYU, Sch Med, Dept Phys Med & Rehabil, New York, NY 10016 USA
[2] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA USA
[5] Univ Washington, Dept Geog, Seattle, WA 98195 USA
[6] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[7] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[8] Univ Washington, Dept Med, Seattle, WA USA
[9] Univ Washington, Dept Family Med, Seattle, WA 98195 USA
[10] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
基金
美国国家科学基金会;
关键词
complementary and alternative medicine; cannabinoid medicine; medical cannabis; cannabinopathic medicine; health-related quality of life; symptom management; SF-36; CDC HRQoL-14;
D O I
10.1177/1049909112454215
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To characterize health-related quality of life (HRQoL) in medical cannabis patients. Methods: Short Form 36 (SF-36) Physical Health Component Score and Mental Health Component Score (MCS) surveys as well has CDC (Centers for Disease Control) HRQoL-14 surveys were completed by 37 qualified patients. Results: Mean SF-36 PCS and MCS, normalized at 50, were 37.4 and 44.2, respectively. Eighty percent of participants reported activity/functional limitations secondary to impairments or health problems. Patients reported using medical cannabis to treat a wide array of symptoms across multiple body systems with relief ratings consistently in the 7-10/10 range. Conclusion: The HRQoL results in this sample of medical cannabis-using patients are comparable with published norms in other chronically ill populations. Data presented provide insight into medical cannabis-using patients' self-rated health, HRQoL, disease incidences, and cannabis-related symptom relief.
引用
收藏
页码:523 / 531
页数:9
相关论文
共 28 条
[21]  
REINMAN A, 2007, COMPLEMENT HLTH PRAC, V12, P31
[22]   Narratives about illness and medication: a neglected theme/new methodology within pharmacy practice research. Part II: medication narratives in practice [J].
Ryan, Kath ;
Bissell, Paul ;
Morecroft, Charles .
PHARMACY WORLD & SCIENCE, 2007, 29 (04) :353-360
[23]   Survey of Australians using cannabis for medical purposes [J].
Swift W. ;
Gates P. ;
Dillon P. .
Harm Reduction Journal, 2 (1)
[24]  
*US BUR CENS, 2006, 2006 POP EST WASH
[25]   Here, there and everywhere: The endocannabinoid system [J].
Vettor, Roberto ;
Pagotto, Uberto ;
Pagano, Claudio ;
Pasquali, Renato .
JOURNAL OF NEUROENDOCRINOLOGY, 2008, 20 :IV-vi
[26]   Adverse effects of medical cannabinoids: a systematic review [J].
Wang, Tongtong ;
Collet, Jean-Paul ;
Shapiro, Stan ;
Ware, Mark A. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 178 (13) :1669-1678
[27]  
Ware J., 1994, SF-36 Physical and Mental Health Summary Scales: A User's Manual
[28]  
Ware J.E., 2003, SF 36 HLTH SURVEY MA, DOI DOI 10.6-10.7